Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback